

Alternatives

Christian Wimmer European Commission - DG Research Health Directorate





Alternative tests: 64 M€ in FP6

Nanotechnology HT techniques Cell chips

Carcinogenicity

Cell array genotoxicity

Development of Specific toxicity assays Reproductive toxicity

Acute toxicity

Skin,
Respiratory
toxicity

Liver, Kidney toxicity

Membrane transport hES cells Hepato toxicity

Liver, Intestine toxicity

Neurotoxicity hESC Cardio-toxicity

3D model Estrogen



STREP

1st call 2nd call 3rd call 4th call 6 Workshops

FP5: 43 projects (**65 M** €) in five specific areas




Alternative testing strategies

- Novel alternative testing strategies for use in pharmaceutical discovery and development.
- Bottlenecks in reduction, refinement and replacement of animal testing in pharmaceutical discovery and development.
- Promotion, development, validation, acceptance and implementation of QSARs for toxicology.
- Alternative testing strategies for the assessment of the toxicological profile of nanoparticles used in medical diagnostics.
- In silico modelling for ADMET outcomes.





FP7 budget (EUR billion)





Coordination of non-Community research programmes

- Coordination of national and regional programmes actions will use the tools:
 - → ERA-NET
 - → ERA-NET PLUS
 - → Article 169

May cover subjects beyond the ten themes

- Coordination with European programmes
 - → Addresses principally intergovernmental structures such as EUREKA, COST, EIROFORUM, etc.





Ideas – Frontier Research

- Frontier Research is a key driver to innovation and economic performance
- Establish European Research Council (ERC) the first pan-European funding agency for Frontier Research
- Support investigator-driven frontier research over all areas of research
- European added-value through competition at European level





Ideas – Frontier Research

- All fields of research are eligible
- no thematic or policy-driven research priorities
- aim to broaden scientific and technological knowledge
- should not be linked to commercial objectives





European Technology Platforms

- Industry-Driven, Competitiveness-Focused
- European Technology Platforms Concept:

Stakeholders, led by industry, get together to define a Strategic Research Agenda on a number of strategically important issues with high societal relevance where achieving Europe's future growth, competitiveness and sustainable objectives is dependent upon major research and technological advances in the medium to long term.





European Technology Platforms

- Bottom-Up Approach with Industry in Lead
- Wide Stakeholder Involvement
- Flexibility: No 'One Size Fits All'
- EU Role: Facilitating and Guiding but not Leading or Owning
- Majority of Strategic Research Agendas, where Appropriate, Taken into Account in Thematic Priorities of FP7
- Minority of Strategic Research Agendas Identified through Dialogue with Industry as Potential 'Joint Technology Initiatives'



Joint Technology Initiatives

May take the form of joint undertakings – Article 171 of the Treaty

'The Community may set up joint undertakings or any other structure necessary for the efficient execution of Community research, technological development and demonstration programmes'





Innovative Medicines Initiative (IMI)

EC challenged industry to identify the bottlenecks to pharmaceutical innovation and where R&D is the key.

Industry via EFPIA's Research Directors Group responded by identifying 4 areas for R&D in agreement with key stakeholders (patients, regulators, clinical and academic researchers, etc.):

- Predictive safety
- Predictive efficacy
- Knowledge management
- Education and training

and the Innovative Medicines Initiaitve (IMI) was created





Information

- EU research: http://europa.eu.int/comm/research
- Seventh Framework Programme: http:// europa.eu.int/comm/research/future/index en.cfm
- Information on research programmes and projects: <u>http://www.cordis.lu</u>
- RTD info magazine: http://europa.eu.int/comm/research/rtdinfo/
- Information requests:
 research@ec.europa.eu



